ArticleScientific reports2025
Two unreported lecanoric acid derivatives isolated from Chaetomium globosum KM651986 and their anti-diabetic effect.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genus Chaetomium, Chaetomiaceae, is a promising source of secondary metabolites with proven pharmacological activities. In the present study, a new strain of Chaetomium globosum (KM651986) was investigated resulting in the isolation of two unreported lecanoric acid derivatives 1 and 2, for the first time, which were analyzed using spectroscopic methods, SwissSimilarity, and SwissTargetPrediction. Thus, predicting the possible biological targets for 1 and 2. Consequently, the crude methanol extract of C. globosum, compounds 1 and 2 were investigated for their anti-diabetic activity using streptozocin (STZ) - induced diabetic rat model. Results indicated that the crude extract C. globosum and compounds 1 and 2 significantly impacted serum glucose, insulin, HbA1c levels, hepatic glucose-6-phosphate dehydrogenase (G6PD) content, cAMP levels, and hepatic α-amylase content. Compound 2 showed a significant decrease in serum glucose by 40% and an increase in insulin level by 65% compared to STZ-diabetic rats, indicating its potent anti-hyperglycemic effect and potential in improving insulin secretion and cell regeneration. Compound 2 also elevated hepatic G6PD, normalized cAMP levels, and decreased hepatic α-amylase, indicating its potential in improving glucose metabolism at the hepatic level. Therefore, compound 2 emerges as particularly promising anti-diabetic candidate meriting further investigation into its potential therapeutic mechanisms of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.